Featured Studies
Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.
- Improving Outcomes for Individuals With Serious Mental Illness and Diabetes.
Interventional study. This project tests a model for improving illness self-management among persons who have both serious mental illness and diabetes and will be performed within a primary care setting at a safety net hospital system. Ages 18 and over. Location in Cleveland, OH.
- Imaging Cannabinoid CB1 Receptors in Schizophrenia.
Evaluation study. Background: - The CB1 receptor is a protein in the brain that is targeted by the active ingredients in cannabis (marijuana). Ages 18-55. Location in Bethesda, MD.
- DECIFER: DEpression and Citalopram In First Episode Recovery.
Interventional study. This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients. Ages 15-40. Location in Boston, MA.
- Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention.
Interventional study. This is a randomized pilot study of an intervention based on principles of Cognitive Behavioral Therapy (CBT). Ages 16-45. Location in Chicago, IL.
- D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia.
Interventional study. This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. Ages 18-65. Location in Boston, MA.
- Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography.
Evaluation study. Background: - Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function. Ages 18-90. Location in Bethesda, MD.
- Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia.
Interventional study. This study will test whether transcranial direct current stimulation (TDCS) can be used safely in children with schizophrenia and if it can improve memory and attention span or auditory hallucinations in these children, at least temporarily. Ages 10-25. Location in Bethesda, MD.
- Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia.
Interventional study. This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make schizophrenics most likely to respond to D-cycloserine treatment. Ages 18-65. Location in Boston, MA.
- Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia.
Interventional study. This study will evaluate the effectiveness of folate and B12 supplementation in reducing negative symptoms in people with schizophrenia. Ages 18-68. Locations in Boston, MA; Grand Rapids, MI; Rochester, NY.
- Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia.
Interventional study. This study will determine the effectiveness of social cognition and interaction training, a manual-based group therapy program, in helping people with schizophrenia improve their social cognition and social functioning. Ages 18-65. Location in Chapel Hill, NC.
- Effects of Motivating People With Schizophrenia to Exercise.
Interventional study. This study will evaluate the impact of motivational guidance to exercise on people with schizophrenia, based on their participation in a walking program. Ages 22 and over. Location in Knoxville, TN.
- A Self-Management Program for Adults With Both Schizophrenia and a Co-Occurring Medical Condition.
Interventional study. This study will develop and evaluate the effectiveness of a self-management program for adults living with both schizophrenia and a co-occurring medical condition. Ages 18-64. Location in Baltimore, MD.
- The Use of Galantamine and CDP-Choline to Treat Adults With Schizophrenia.
Interventional study. This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia. Ages 18-70. Location in Washington, DC.
- Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses.
Interventional study. This study will determine the effectiveness of a peer support system in increasing physical activity and effecting health behavior change in people with serious mental illnesses. Ages 18-70. Location in Baltimore, MD.
- Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia.
Interventional study. This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive and perceptual disturbances and symptoms in Chinese people with schizophrenia. Ages 18-64. Locations in Houston, TX; Beijing, China.
- Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia.
Interventional study. This study will determine the comparative effectiveness of two systems designed to improve medication adherence in people with schizophrenia. Ages 18-60. Location in San Antonio, TX.
- Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia.
Interventional study. This study will evaluate the effectiveness of attention shaping procedures in improving attentiveness and learning abilities in people undergoing psychosocial skills training treatment for schizophrenia. Ages 18-55. Locations in Monmouth Junction, NJ; New Brunswick, NJ.
- Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia.
Interventional study. This study will evaluate the effectiveness of a culturally based family therapy intervention in improving treatment outcome in people with schizophrenia. Ages 13 and over. Location in Coral Gables, FL.
- Guanfacine for Improving Cognitive Symptoms in People With Schizotypal Personality Disorder.
Interventional study. This study will determine the effectiveness of guanfacine in improving symptoms of schizotypal personality disorder. Ages 18-60. Location in New York, NY.
- Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia.
Interventional study. This study will evaluate the effectiveness of a lifestyle intervention in increasing physical activity and reducing disease symptoms in sedentary adults with schizophrenia. Ages 21-64. Location in La Jolla, CA.
- Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia.
Interventional study. This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia. Ages 18-45. Location in Los Angeles, CA.
- Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia.
Interventional study. This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia. Ages 18-45. Location in Los Angeles, CA.
- Transcranial Magnetic Stimulation for "Voices".
Interventional study. This study will determine the efficacy of MRI-guided transcranial magnetic stimulation (TMS)in reducing "voices" and other symptoms experienced by people with schizophrenia and schizoaffective disorder. Ages 18-55. Location in New Haven, CT.
- Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis.
Interventional study. This study will determine the effectiveness of the Graduated Recovery Intervention Program, a manual-based individual therapy program, in enhancing the clinical benefit of routine treatment for individuals recovering from their first episodes of psychosis. Ages 18 and over. Location in Chapel Hill, NC.
- Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients.
Interventional study. This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia. Ages 18-60. Location in Denver, CO.
- D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia.
Interventional study. This study will examine the effectiveness of D-serine in increasing and sustaining the benefits of cognitive retraining in people with schizophrenia. Ages 18-65. Location in Bangalore, India.
- Determining Metabolic Effects of Valproate and Antipsychotic Therapy.
Interventional study. This study will determine the metabolic processes responsible for high levels of blood glucose, metabolism disorders, and weight gain in people with schizophrenia who have been treated with antipsychotic medications in combination with valproate. Ages 18-60. Location in St. Louis, MO.
- Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia.
Interventional study. This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia. Ages 18-65. Locations in New York, NY; W. Brentwood, NY.
- Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia.
Interventional study. This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics. Ages 18-55. Location in Denver, CO.
- Effects of Modafinil on Brain Function in Patients With Schizophrenia.
Interventional study. This study will evaluate whether modafinil improves cognition in patients with schizophrenia and healthy volunteers. Ages 18-50. Location in Bethesda, MD.
- Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine.
Interventional study. This study will determine whether adding the drug risperidone (Risperdal®) is more effective than placebo in treating schizophrenic patients who are taking the drug clozapine. Ages 18-65. Location in Baltimore, MD.
- Screening for Childhood-Onset Psychotic Disorders.
Evaluation study. The purpose of this study is to screen and evaluate children with psychotic disorders to establish or confirm their diagnosis and to collect data about their condition. Ages 5-18. Location in Bethesda, MD.
- Clinical Trial of Tolcapone for Cognition in Schizophrenia.
Interventional study. This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Ages 18-50. Location in Bethesda, MD.
- Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers.
Evaluation study. The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. Ages 18 and over. Location in Bethesda, MD.
- Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings.
Evaluation study. This study will explore how the brain works during memory testing in an effort to understand why some patients with schizophrenia have memory difficulties. Ages 18-55. Location in Bethesda, MD.
- Inpatient Evaluation of Adults With Schizophrenia.
Evaluation study. The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness. Ages 18 and over. Location in Bethesda, MD.
- Studies of Frontal Lobe Brain Functioning in Schizophrenia.
Evaluation study. The purpose of this study is to use brain imaging technology to investigate the role of the frontal lobe of the brain in the thinking of individuals with schizophrenia and other neuropsychiatric disorders and healthy volunteers. Ages 18-90. Location in Bethesda, MD.
- Brain Tissue Collection for Neuropathological Studies.
Evaluation study. The purpose of this study is to collect and study the brain tissue of deceased individuals to learn more about the nervous system and mental disorders. Locations in Washington, DC; Bethesda, MD; Fairfax, VA.
- Evaluation of the Genetics of Bipolar Disorder.
Evaluation study. This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions. Ages 18 and over. Location in Bethesda, MD.
- Genetic Study of Schizophrenia.
Evaluation study. This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness. Ages 18 and over. Location in Bethesda, MD.
- Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia.
Evaluation study. A study of children and adolescents (current N=100) with very early onset by age 12 (COS) of DSM-III-R defined schizophrenia with (97-M-0126) is examining the clinical, neurobiological, early neurodevelopmental, genetic, and clinical drug response characteristics of these cases. Ages 6 and over. Location in Bethesda, MD.
Search ClinicalTrials.gov for other NIH studies on Schizophrenia.
Related Information
- Learn more about Schizophrenia
Schizophrenia is a devastating brain disorder — the most chronic and disabling of the severe mental illnesses. People with schizophrenia often suffer terrifying symptoms such as hearing internal voices not heard by others, or believing that other people are reading their minds, controlling their thoughts, or plotting to harm them. These symptoms may leave them fearful and withdrawn.
Clinical Research at NIMH
- For opportunities to participate in NIMH research on the NIH campus, visit the patient recruitment Website. Travel and lodging assistance available.
